New Studies Highlight Performance of Vectra Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab
Myriad Genetics (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra that evaluated the test’s ability to track treatment response in patients with rheumatoid arthritis (RA). As quoted in the press release: “We are committed to advancing the knowledge of the Vectra test for rheumatologists and their patients with … Continued
Myriad Genetics (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra that evaluated the test’s ability to track treatment response in patients with rheumatoid arthritis (RA).
As quoted in the press release:
“We are committed to advancing the knowledge of the Vectra test for rheumatologists and their patients with rheumatoid arthritis. This year we are highlighting two new studies that demonstrate the performance of Vectra in patients treated with Ritaximab and Tofacitinib,” said Elena Hitraya, M.D., Ph.D., chief medical officer, Myriad Autoimmune. “The goal is to provide rheumatologists with objective molecular information that can enable better patient management.”
Vectra is the leading personalized medicine test for patients with RA, and it is used to assess changes in disease activity. In a recently presented analysis based on multiple studies, Vectra was shown to be three times more effective at predicting radiographic progression in patients with RA compared to other measures of disease activity.
